Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Auteurs principaux: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Format: | Journal article |
Publié: |
Lancet
2016
|
Documents similaires
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
par: Glaire, MA, et autres
Publié: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
par: Van Gool, I, et autres
Publié: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
par: Klenerman, P, et autres
Publié: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
par: Van Gool, I, et autres
Publié: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
par: Rayner, E, et autres
Publié: (2016)